Entrodyne Pharmaceuticals

Entrodyne Pharmaceuticals

In 1972, a man named George Lansing opened Lansing Pharmaceuticals which helped the Ottawa Health Research Institute (OHRI) with cancer therapeutics; clinical epidemiology; diseases of ageing; hormones, growth, and development; molecular medicine; neuroscience, and vision.

Over the years, Mister Lansing found it easier to go with the flow instead of compete with stronger companies and sold Lansing Pharmaceuticals to Entrodyne for an undisclosed sum. Although he remained Chief Executive Officer of EP for several years after, he retired happily and still advises the company through his daughter, Chantelle, and was integral in helping move productions from the east of Orleans to Kanata, south of Scotiabank Place.

Chantelle Lansing-Lords, only child of George Lansing, became CEO in the late 2000’s and has worked as fervently as her father had in enabling the company to grow while providing the city (and most of Eastern Ontario) with its products. Although accused several times of nepotism, Chantelle has proven her worth time and time again, often referring to her husband and Chief Financial Officer, Roger Lords.

Both Chantelle and Roger have come under fire, both internally and externally for their closeness. Their actions are always under scrutiny, but no one can suggest for a moment that their relationship has, in any way, defamed or hampered the production or progression of the company.

What is public knowledge is that while Entrodyne bought out Lansing Pharmaceuticals, Entrodyne is itself a subsidiary of a larger, global medical company named Hike Industries, and that it was Chantelle who – fifteen years ago – suggested to her father that the merger (and eventual buy-out) would be beneficial to the fledgling company.

Entrodyne Pharmaceuticals

Tales by the Fire presents ... Great_Owl Great_Owl